BLA 761204 · Amicus Therap US
Pombiliti
Cipaglucosidase Alfa-Atga · Injection
NovelBreakthrough therapyOrphanCDER novel approval, Sep 28, 2023: To treat late-onset Pompe disease
Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 28, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
4 Phase 3, 2 recruiting
FAERS reports
91
47 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS Hypersensitivity Reactions Including Anaphylaxis Patients treated with POMBILITI have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during POMBILITI administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, POMBILITI should be discontinued immediately, and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, desensitization measures to POMBILITI may be considered [see Warnings and Precautions (5.1) ]. Infusion-Associated Reactions (IARs) Patients treated with POMBILITI have experienced severe IARs. If severe IARs occur,...
What it is approved for
From the label in effect Aug 12, 2026.
POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). POMBILITI is a hydrolytic lysosomal glycogen-specific enzyme indicated, in combination with Opfolda, an enzyme stabilizer, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )
Mechanism: Pompe disease (also known as glycogen storage disease type II, acid maltase deficiency, and glycogenosis type II) is an inherited disorder of glycogen metabolism caused by a deficiency of lysosomal acid alpha‑glucosidase (GAA) that degrades glycogen to glucose in the lysosome. GAA deficiency results in intra-lysosomal accumulation of glycogen in various tissues. Cipaglucosidase alfa-atga provides an exogenous source of GAA. The bis-M6P on cipaglucosidase alfa-atga mediates binding to M6P receptors on the cell surface with high affinity. After binding, it is internalized and transported into...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2023 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- POMBILITI · CIPAGLUCOSIDASE ALFA-ATGA 105MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cipaglucosidase Alfa" as an intervention, any sponsor and status, largest first.
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)Pivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT04138277 · 119 participants · Start Dec 18, 2019 · Primary completion Dec 31, 2024
Drug: AT2221; ATB200 · For: Pompe Disease (Late-onset)
Sites: Little Rock, Arkansas; Irvine, California; Gainesville, Florida · 60 sites in all
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
Amicus TherapeuticsIndustry
NCT02675465 · 29 participants · Start Apr 2016 · Primary completion Aug 22, 2024
Drug: ATB200; AT2221 · For: Pompe Disease
Sites: Phoenix, Arizona; Orange, California; Gainesville, Florida · 19 sites in all
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPivotal-lookingActive, not recruiting
Amicus TherapeuticsIndustry
NCT03911505 · 21 participants · Start Feb 13, 2020 · Primary completion Mar 2027
Drug: Cipaglucosidase Alfa; Miglustat · For: Pompe Disease (Late-onset)
Sites: Gainesville, Florida; Jacksonville, Florida; Atlanta, Georgia · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue10
- nausea10
- asthenia7
- product dose omission issue7
- vomiting7
- malaise6
- death5
- dyspnoea5
- headache5
- hypertension5
- infusion related reaction5
- pneumonia5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 28 |
| 2025 | 30 |
| 2026 | 33 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pombiliti (Cipaglucosidase Alfa-Atga)
2024 spending
$5.8M
Beneficiaries
13
107 claims
Per beneficiary
$445,836
$1,818.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $5,795,874 |
Part B: Pombiliti (Cipaglucosidase Alfa-Atga) · HCPCS J1203
2024 spending
$2.7M
Beneficiaries
13
87 claims
Per beneficiary
$207,185
2024 ASP limit $88.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,693,409 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, et al. · J Neurol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Enzyme replacement therapy for late-onset Pompe disease.
Dalmia S, Sharma R, Ramaswami U, et al. · Cochrane Database Syst Rev 2023 · Systematic Review
- Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Byrne BJ, Schoser B, Kishnani PS, et al. · J Neurol 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data.
Fu S, Hummel N, Shohet S, et al. · J Comp Eff Res 2026 · Network Meta-Analysis, Comparative Study
Sponsor: Amicus Therap US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.